drugset
drugset / Trial / NCT02071823

Comparative Bioavailability Study of BIA 9-1067 25 mg Capsules

NCT02071823 ↗

Phase 1 Completed 12 enrolled Bial - Portela C S.A.
RandomizedCrossoverOpen-labelTreatment

Summary

The objectives of this study were to characterize the effects of food on the pharmacokinetics (PK) and tolerability of BIA 9-1067 in healthy male subjects.

Timeline

Start
2008-05
Primary completion
2008-06
Completion
2008-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Opicapone Small molecule 50 mg Oral

Indications

Parkinson disease